Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
NBI-98854 Phase III trial in tardive dyskinesia
.
Show all posts
Showing posts with label
NBI-98854 Phase III trial in tardive dyskinesia
.
Show all posts
Friday, October 30, 2015
Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia
›
Neurocrine Biosciences, Inc. announced that NBI-98854 , a highly selective small molecule VMAT2 inhibitor, showed a statistically ...
›
Home
View web version
